These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7930703)

  • 1. Does early zidovudine treatment prevent the emergency of syncytium-inducing human immunodeficiency virus?
    Leal M; Torres Y; Medrano FJ; Calderón EJ; Rey C; Lissen E
    J Infect Dis; 1994 Oct; 170(4):1041-2. PubMed ID: 7930703
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
    Koot M; Schellekens PT; Mulder JW; Lange JM; Roos MT; Coutinho RA; Tersmette M; Miedema F
    J Infect Dis; 1993 Sep; 168(3):733-6. PubMed ID: 8102631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine response relationships in early human immunodeficiency virus infection.
    Sale M; Sheiner LB; Volberding P; Blaschke TF
    Clin Pharmacol Ther; 1993 Nov; 54(5):556-66. PubMed ID: 7900949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
    Tersmette M; Lange JM; de Goede RE; de Wolf F; Eeftink-Schattenkerk JK; Schellekens PT; Coutinho RA; Huisman JG; Goudsmit J; Miedema F
    Lancet; 1989 May; 1(8645):983-5. PubMed ID: 2565516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Survival of patients with zidovudine resistant HIV].
    Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
    Ugeskr Laeger; 1994 Jan; 156(2):185-6. PubMed ID: 7905217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Controversies concerning the use of zidovudine in the treatment of asymptomatic HIV+ subjects with a low number of CD4+ lymphocytes].
    Sarmati L; Vella S; Rocchi G
    Medicina (Firenze); 1990; 10(2):195-7. PubMed ID: 2273959
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen.
    Anderson DJ; O'Brien TR; Politch JA; Martinez A; Seage GR; Padian N; Horsburgh CR; Mayer KH
    JAMA; 1992 May; 267(20):2769-74. PubMed ID: 1349654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
    de Jong MD; Veenstra J; Stilianakis NI; Schuurman R; Lange JM; de Boer RJ; Boucher CA
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5501-6. PubMed ID: 8643604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals.
    Guiguet M; Mary M; Costagliola D; Armengaud M; Cartier F; Micoud M; Mouton Y; Sobesky G; Valleron AJ
    AIDS; 1992 Nov; 6(11):1405-6. PubMed ID: 1361751
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine.
    Delforge ML; Liesnard C; Debaisieux L; Tchetcheroff M; Farber CM; Van Vooren JP
    AIDS; 1995 Jan; 9(1):89-90. PubMed ID: 7893446
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy.
    Graham NM; Park LP; Piantadosi S; Phair JP; Mellors J; Fahey JL; Saah AJ
    Clin Infect Dis; 1995 Feb; 20(2):352-62. PubMed ID: 7742442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of zidovudine on neuropsychiatric measures in HIV-infected men.
    Gorman JM; Mayeux R; Stern Y; Williams JB; Rabkin J; Goetz RR; Ehrhardt AA
    Am J Psychiatry; 1993 Mar; 150(3):505-7. PubMed ID: 8094601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of antiviral therapy on the natural history of HIV infection.
    Phillips AN; Keenlyside R; Johnson AM
    J Acquir Immune Defic Syndr (1988); 1992 Oct; 5(10):1065-6. PubMed ID: 1453323
    [No Abstract]   [Full Text] [Related]  

  • 14. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: implications for interrupting vertical transmission.
    Jackson JB
    Pediatr AIDS HIV Infect; 1995 Dec; 6(6):358-9. PubMed ID: 11361462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zidovudine improves psoriasis in human immunodeficiency virus-positive males.
    Duvic M; Crane MM; Conant M; Mahoney SE; Reveille JD; Lehrman SN
    Arch Dermatol; 1994 Apr; 130(4):447-51. PubMed ID: 7909423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy.
    Krieger JN; Coombs RW; Collier AC; Ross SO; Chaloupka K; Cummings DK; Murphy VL; Corey L
    J Infect Dis; 1991 Feb; 163(2):386-8. PubMed ID: 1988523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syncytium forming capacity of HIV 1 strains in inhibited by pretreatment of CD4 expressing cells with 3'-azido-3'-deoxythymidine but not by alpha interferon.
    Ruţă SM; Cernescu C
    Rev Roum Virol; 1994; 45(3-4):171-83. PubMed ID: 7619738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.